Lilly’s Mirikizumab Hits All Marks In First Phase III Study For UC

 
• By Joseph Haas

Antibody targeting IL-23p19 yields clinical remission of ulcerative colitis after 12 weeks in the Phase III LUCENT-1 study. It also met all secondary endpoints, including reduction of bowel urgency.

Lilly gets positive Phase III data for its anti-IL-23 candidate in ulcerative colitis

More from Clinical Trials

More from R&D